Tirzepatide vs. Semaglutide: How Do They Actually Compare?

Direct Answer

Tirzepatide and semaglutide are both GLP-1 medications, but they work through genuinely different mechanisms. Semaglutide (Ozempic, Wegovy) activates only the GLP-1 receptor. Tirzepatide (Mounjaro, Zepbound) activates both the GLP-1 and GIP receptors, a real, dual-mechanism difference that shows up directly in the data.

The Real Effectiveness Difference

Across trial data, tirzepatide has consistently shown stronger average weight loss, roughly 15-22% of body weight, compared to semaglutide's roughly 10-15%. Both are genuinely effective; tirzepatide's dual-receptor mechanism is the most commonly cited explanation for its stronger average results.

A Real, Practical Tradeoff

Semaglutide offers real, meaningful advantages of its own: a longer track record (more established real-world data), typically lower cost, and, for people who want strong results at a somewhat gentler dose escalation, a real, reasonable middle path. Tirzepatide's stronger average effectiveness comes alongside real, generally similar gastrointestinal side effects.

Bottom Line

Neither medication is universally "better", tirzepatide shows stronger average weight-loss data, while semaglutide offers a longer track record and often lower cost. The right choice depends on your specific health profile and goals, worth discussing directly with your provider.

References

• SURMOUNT and STEP trial program data (Eli Lilly, Novo Nordisk)

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Get Started

Explore the GLP-1 Tracker knowledge base for accurate, sourced information on every GLP-1 medication.

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This article is for general informational purposes and is not medical advice.